Literature DB >> 20497051

Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan.

Jeniel E Nett1, Hiram Sanchez, Michael T Cain, David R Andes.   

Abstract

Medical devices provide an ecological niche for microbes to flourish as a biofilm community, protected from antimicrobials and host defenses. Biofilms formed by Candida albicans, the most common fungal pathogen, survive exposure to extraordinarily high drug concentrations. Here, we show that beta-glucan synthase Fks1p produces glucan, which is deposited in the biofilm matrix. The extracellular glucan is required for biofilm resistance and acts by sequestering antifungals, rendering cells resistant to their action. These findings provide the genetic basis for how biofilm matrix production governs drug resistance by impeding drug diffusion and also identify a useful biofilm drug target.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20497051      PMCID: PMC2880631          DOI: 10.1086/651200

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Use of an animal model of disseminated candidiasis in the evaluation of antifungal therapy.

Authors:  David Andes
Journal:  Methods Mol Med       Date:  2005

2.  Cloning of the Candida albicans homolog of Saccharomyces cerevisiae GSC1/FKS1 and its involvement in beta-1,3-glucan synthesis.

Authors:  T Mio; M Adachi-Shimizu; Y Tachibana; H Tabuchi; S B Inoue; T Yabe; T Yamada-Okabe; M Arisawa; T Watanabe; H Yamada-Okabe
Journal:  J Bacteriol       Date:  1997-07       Impact factor: 3.490

3.  RIM101-dependent and-independent pathways govern pH responses in Candida albicans.

Authors:  D Davis; R B Wilson; A P Mitchell
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

4.  Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance.

Authors:  Mohammed A Al-Fattani; L Julia Douglas
Journal:  J Med Microbiol       Date:  2006-08       Impact factor: 2.472

5.  Development and characterization of an in vivo central venous catheter Candida albicans biofilm model.

Authors:  D Andes; J Nett; P Oschel; R Albrecht; K Marchillo; A Pitula
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

6.  New modules for PCR-based gene targeting in Candida albicans: rapid and efficient gene targeting using 100 bp of flanking homology region.

Authors:  Susanne Gola; Ronny Martin; Andrea Walther; Alexander Dünkler; Jürgen Wendland
Journal:  Yeast       Date:  2003-12       Impact factor: 3.239

7.  Large-scale essential gene identification in Candida albicans and applications to antifungal drug discovery.

Authors:  Terry Roemer; Bo Jiang; John Davison; Troy Ketela; Karynn Veillette; Anouk Breton; Fatou Tandia; Annie Linteau; Susan Sillaots; Catarina Marta; Nick Martel; Steeve Veronneau; Sebastien Lemieux; Sarah Kauffman; Jeff Becker; Reginald Storms; Charles Boone; Howard Bussey
Journal:  Mol Microbiol       Date:  2003-10       Impact factor: 3.501

8.  Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols.

Authors:  Pranab K Mukherjee; Jyotsna Chandra; Duncan M Kuhn; Mahmoud A Ghannoum
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

9.  Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters.

Authors:  D Sanglard; K Kuchler; F Ischer; J L Pagani; M Monod; J Bille
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

10.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David Andes; Daniel K Benjamin; Thierry F Calandra; John E Edwards; Scott G Filler; John F Fisher; Bart-Jan Kullberg; Luis Ostrosky-Zeichner; Annette C Reboli; John H Rex; Thomas J Walsh; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079

View more
  97 in total

Review 1.  Candida albicans Biofilms and Human Disease.

Authors:  Clarissa J Nobile; Alexander D Johnson
Journal:  Annu Rev Microbiol       Date:  2015       Impact factor: 15.500

2.  Genetic control of Candida albicans biofilm development.

Authors:  Jonathan S Finkel; Aaron P Mitchell
Journal:  Nat Rev Microbiol       Date:  2010-12-29       Impact factor: 60.633

3.  Sustained release of a novel anti-quorum-sensing agent against oral fungal biofilms.

Authors:  Mark Feldman; Julia Shenderovich; Abed Al Aziz Al-Quntar; Michael Friedman; Doron Steinberg
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

4.  In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species.

Authors:  Barbara Fiori; Brunella Posteraro; Riccardo Torelli; Mario Tumbarello; David S Perlin; Giovanni Fadda; Maurizio Sanguinetti
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

5.  Symbiotic relationship between Streptococcus mutans and Candida albicans synergizes virulence of plaque biofilms in vivo.

Authors:  Megan L Falsetta; Marlise I Klein; Punsiri M Colonne; Kathleen Scott-Anne; Stacy Gregoire; Chia-Hua Pai; Mireya Gonzalez-Begne; Gene Watson; Damian J Krysan; William H Bowen; Hyun Koo
Journal:  Infect Immun       Date:  2014-02-24       Impact factor: 3.441

Review 6.  Mechanisms of Antifungal Drug Resistance.

Authors:  Leah E Cowen; Dominique Sanglard; Susan J Howard; P David Rogers; David S Perlin
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-10       Impact factor: 6.915

7.  Global transcriptome changes underlying colony growth in the opportunistic human pathogen Aspergillus fumigatus.

Authors:  John G Gibbons; Anne Beauvais; Remi Beau; Kriston L McGary; Jean-Paul Latgé; Antonis Rokas
Journal:  Eukaryot Cell       Date:  2011-07-01

8.  Candida albicans biofilms do not trigger reactive oxygen species and evade neutrophil killing.

Authors:  Zhihong Xie; Angela Thompson; Takanori Sobue; Helena Kashleva; Hongbin Xu; John Vasilakos; Anna Dongari-Bagtzoglou
Journal:  J Infect Dis       Date:  2012-10-02       Impact factor: 5.226

9.  Small-molecule suppressors of Candida albicans biofilm formation synergistically enhance the antifungal activity of amphotericin B against clinical Candida isolates.

Authors:  Jianlan You; Lin Du; Jarrod B King; Brian E Hall; Robert H Cichewicz
Journal:  ACS Chem Biol       Date:  2013-02-14       Impact factor: 5.100

Review 10.  Antifungal lock therapy.

Authors:  Carla J Walraven; Samuel A Lee
Journal:  Antimicrob Agents Chemother       Date:  2012-10-15       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.